Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali

B. Diarra; T. Decroo; A. Somboro; G. Coulibaly; M. Tolofoudie; M. Kone; B. Degoga; F. Diallo; A. C. G. Togo; M. Sanogo; Y. S. Sarro; A. B. Cisse; O. Kodio; B. Baya; A. Kone; M. Maiga; S. Dao; I. I. Maiga; R. L. Murphy; S. Siddiqui; Y. Toloba; B. Konate; M. Diakite; S. Doumbia; A. Van Deun; L. Rigouts; S. Diallo; B. C. de Jong

doi:10.5588/ijtld.19.0698

Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali

B. Diarra, T. Decroo, A. Somboro, G. Coulibaly, M. Tolofoudie, M. Kone, B. Degoga, F. Diallo, A. C. G. Togo, M. Sanogo, Y. S. Sarro, A. B. Cisse, O. Kodio, B. Baya, A. Kone, M. Maiga, S. Dao, I. I. Maiga, R. L. Murphy, S. SiddiquiY. Toloba, B. Konate, M. Diakite, S. Doumbia, A. Van Deun, L. Rigouts, S. Diallo, B. C. de Jong

Research output: Contribution to journal › A1: Web of Science-article › peer-review

7 Downloads (Pure)

Abstract

BACKGROUND: Non-conversion on auramine smear microscopy indicates a lack of treatment response, possibly associated with initial rifampicin-resistant tuberculosis (RR-TB). However, dead bacteria still stain positive and may be detected. Fluorescein diacetate smear microscopy (FDA) shows live mycobacteria only. Therefore, we studied the potential of 2-month (2M) FDA for the identification of initial RR-TB.

METHODS: Between 2015 and 2018, we enrolled new smear-positive pulmonary TB patients from five local centres in Bamako, Mali. After baseline screening, sputum samples were collected at 1M, 2M, 5M and 18M. We used rpoB sequencing to identify initial RR-TB.

RESULTS: Of 1359 patients enrolled, 1019 (75%) had rpoB sequencing results. Twenty-six (2.6%, 95%CI: 1.7-3.7) had mutations conferring rifampicin resistance. Most frequent rpoB mutations were located at the codons Asp435Val (42.4%) and Ser450Leu (34.7%). Among patients with initial RR-TB, 72.2% were FDA-negative at 2M (P = 0.2). The positive and negative predictive value of 5M FDA for culture-based failure was respectively 20.0% and 94.7%.

CONCLUSION: FDA did not identify the majority of patients with initial RR-TB or culture-based failure. As the full spectrum of mutations identified on sequencing was identified using Xpert, our data support its rapid universal implementation in Mali.

Original language	English
Journal	International Journal of Tuberculosis and Lung Disease
Volume	24
Issue number	8
Pages (from-to)	763-769
Number of pages	8
ISSN	1027-3719
DOIs	https://doi.org/10.5588/ijtld.19.0698
Publication status	Published - 2020

Keywords

FDA
sequencing
rpoB
Mali
MYCOBACTERIUM-TUBERCULOSIS
MICROSCOPY
DIAGNOSIS

Access to Document

10.5588/ijtld.19.0698Licence: Unspecified

2020ijtl0763Final published version, 204 KBLicence: Unspecified

Cite this

Diarra, B., Decroo, T., Somboro, A., Coulibaly, G., Tolofoudie, M., Kone, M., Degoga, B., Diallo, F., Togo, A. C. G., Sanogo, M., Sarro, Y. S., Cisse, A. B., Kodio, O., Baya, B., Kone, A., Maiga, M., Dao, S., Maiga, I. I., Murphy, R. L., ... de Jong, B. C. (2020). Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali. International Journal of Tuberculosis and Lung Disease, 24(8), 763-769. https://doi.org/10.5588/ijtld.19.0698

@article{e01fd0420f624efc8b0e90aeaab9ca21,

title = "Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali",

abstract = "BACKGROUND: Non-conversion on auramine smear microscopy indicates a lack of treatment response, possibly associated with initial rifampicin-resistant tuberculosis (RR-TB). However, dead bacteria still stain positive and may be detected. Fluorescein diacetate smear microscopy (FDA) shows live mycobacteria only. Therefore, we studied the potential of 2-month (2M) FDA for the identification of initial RR-TB.METHODS: Between 2015 and 2018, we enrolled new smear-positive pulmonary TB patients from five local centres in Bamako, Mali. After baseline screening, sputum samples were collected at 1M, 2M, 5M and 18M. We used rpoB sequencing to identify initial RR-TB.RESULTS: Of 1359 patients enrolled, 1019 (75%) had rpoB sequencing results. Twenty-six (2.6%, 95%CI: 1.7-3.7) had mutations conferring rifampicin resistance. Most frequent rpoB mutations were located at the codons Asp435Val (42.4%) and Ser450Leu (34.7%). Among patients with initial RR-TB, 72.2% were FDA-negative at 2M (P = 0.2). The positive and negative predictive value of 5M FDA for culture-based failure was respectively 20.0% and 94.7%.CONCLUSION: FDA did not identify the majority of patients with initial RR-TB or culture-based failure. As the full spectrum of mutations identified on sequencing was identified using Xpert, our data support its rapid universal implementation in Mali.",

keywords = "FDA, sequencing, rpoB, Mali, MYCOBACTERIUM-TUBERCULOSIS, MICROSCOPY, DIAGNOSIS",

author = "B. Diarra and T. Decroo and A. Somboro and G. Coulibaly and M. Tolofoudie and M. Kone and B. Degoga and F. Diallo and Togo, {A. C. G.} and M. Sanogo and Sarro, {Y. S.} and Cisse, {A. B.} and O. Kodio and B. Baya and A. Kone and M. Maiga and S. Dao and Maiga, {I. I.} and Murphy, {R. L.} and S. Siddiqui and Y. Toloba and B. Konate and M. Diakite and S. Doumbia and {Van Deun}, A. and L. Rigouts and S. Diallo and {de Jong}, {B. C.}",

note = "FTX",

year = "2020",

doi = "10.5588/ijtld.19.0698",

language = "English",

volume = "24",

pages = "763--769",

journal = "International Journal of Tuberculosis and Lung Disease",

issn = "1027-3719",

publisher = "International Union Against Tuberculosis and Lung Disease",

number = "8",

}

Diarra, B, Decroo, T, Somboro, A, Coulibaly, G, Tolofoudie, M, Kone, M, Degoga, B, Diallo, F, Togo, ACG, Sanogo, M, Sarro, YS, Cisse, AB, Kodio, O, Baya, B, Kone, A, Maiga, M, Dao, S, Maiga, II, Murphy, RL, Siddiqui, S, Toloba, Y, Konate, B, Diakite, M, Doumbia, S, Van Deun, A, Rigouts, L, Diallo, S & de Jong, BC 2020, 'Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali', International Journal of Tuberculosis and Lung Disease, vol. 24, no. 8, pp. 763-769. https://doi.org/10.5588/ijtld.19.0698

TY - JOUR

T1 - Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali

AU - Diarra, B.

AU - Decroo, T.

AU - Somboro, A.

AU - Coulibaly, G.

AU - Tolofoudie, M.

AU - Kone, M.

AU - Degoga, B.

AU - Diallo, F.

AU - Togo, A. C. G.

AU - Sanogo, M.

AU - Sarro, Y. S.

AU - Cisse, A. B.

AU - Kodio, O.

AU - Baya, B.

AU - Kone, A.

AU - Maiga, M.

AU - Dao, S.

AU - Maiga, I. I.

AU - Murphy, R. L.

AU - Siddiqui, S.

AU - Toloba, Y.

AU - Konate, B.

AU - Diakite, M.

AU - Doumbia, S.

AU - Van Deun, A.

AU - Rigouts, L.

AU - Diallo, S.

AU - de Jong, B. C.

N1 - FTX

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Non-conversion on auramine smear microscopy indicates a lack of treatment response, possibly associated with initial rifampicin-resistant tuberculosis (RR-TB). However, dead bacteria still stain positive and may be detected. Fluorescein diacetate smear microscopy (FDA) shows live mycobacteria only. Therefore, we studied the potential of 2-month (2M) FDA for the identification of initial RR-TB.METHODS: Between 2015 and 2018, we enrolled new smear-positive pulmonary TB patients from five local centres in Bamako, Mali. After baseline screening, sputum samples were collected at 1M, 2M, 5M and 18M. We used rpoB sequencing to identify initial RR-TB.RESULTS: Of 1359 patients enrolled, 1019 (75%) had rpoB sequencing results. Twenty-six (2.6%, 95%CI: 1.7-3.7) had mutations conferring rifampicin resistance. Most frequent rpoB mutations were located at the codons Asp435Val (42.4%) and Ser450Leu (34.7%). Among patients with initial RR-TB, 72.2% were FDA-negative at 2M (P = 0.2). The positive and negative predictive value of 5M FDA for culture-based failure was respectively 20.0% and 94.7%.CONCLUSION: FDA did not identify the majority of patients with initial RR-TB or culture-based failure. As the full spectrum of mutations identified on sequencing was identified using Xpert, our data support its rapid universal implementation in Mali.

AB - BACKGROUND: Non-conversion on auramine smear microscopy indicates a lack of treatment response, possibly associated with initial rifampicin-resistant tuberculosis (RR-TB). However, dead bacteria still stain positive and may be detected. Fluorescein diacetate smear microscopy (FDA) shows live mycobacteria only. Therefore, we studied the potential of 2-month (2M) FDA for the identification of initial RR-TB.METHODS: Between 2015 and 2018, we enrolled new smear-positive pulmonary TB patients from five local centres in Bamako, Mali. After baseline screening, sputum samples were collected at 1M, 2M, 5M and 18M. We used rpoB sequencing to identify initial RR-TB.RESULTS: Of 1359 patients enrolled, 1019 (75%) had rpoB sequencing results. Twenty-six (2.6%, 95%CI: 1.7-3.7) had mutations conferring rifampicin resistance. Most frequent rpoB mutations were located at the codons Asp435Val (42.4%) and Ser450Leu (34.7%). Among patients with initial RR-TB, 72.2% were FDA-negative at 2M (P = 0.2). The positive and negative predictive value of 5M FDA for culture-based failure was respectively 20.0% and 94.7%.CONCLUSION: FDA did not identify the majority of patients with initial RR-TB or culture-based failure. As the full spectrum of mutations identified on sequencing was identified using Xpert, our data support its rapid universal implementation in Mali.

KW - FDA

KW - sequencing

KW - rpoB

KW - Mali

KW - MYCOBACTERIUM-TUBERCULOSIS

KW - MICROSCOPY

KW - DIAGNOSIS

U2 - 10.5588/ijtld.19.0698

DO - 10.5588/ijtld.19.0698

M3 - A1: Web of Science-article

SN - 1027-3719

VL - 24

SP - 763

EP - 769

JO - International Journal of Tuberculosis and Lung Disease

JF - International Journal of Tuberculosis and Lung Disease

IS - 8

ER -

Fluorescein diacetate and rapid molecular testing for the early identification of rifampicin resistance in Mali

Abstract

Keywords

Access to Document

Fingerprint

Cite this